Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection

• Status: Completed
• Trial end date: 2005-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial tests the safety and effectiveness of the early use of combinations of anti-HIV drugs in HIV-infected infants and young children in an effort to block virus growth and preserve normal immune functions.

Various anti-HIV drug combinations need to be tested in order to find the best way to treat infants and children who have been infected with HIV during birth.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
• Collaborator: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
• Treatments: Abacavir; Lamivudine; Nelfinavir; Nevirapine; Stavudine; Zidovudine

Criteria

Inclusion Criteria

Children may be eligible for this study if they:

• Are 15 days to 2 years old.

• Have consent of parent or legal guardian.

• Are HIV-positive.

Exclusion Criteria

Children will not be eligible for this study if they:

• Have certain infections which require treatment during the study.

• Have received certain medications.